Clinical trials: Cardiovascular Effects
Hypertension
The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)
This study will test the relationship between CBP (central blood pressure) and PBP (peripheral blood pressure) effects after single and multiple doses of Isosorbide mononitrate extended release (ISMN ER) or Amlodipine besylate in…
- Trial name
- NCT01130168
- Testing
- Comparator: Amlodipine, Comparator: ISMN ER
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Peripheral Artery Disease
Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease
This study was designed to assess the safety, tolerability and efficacy of ACZ885 on the leg artery structure and physical activity in patients with atherosclerotic peripheral artery disease and leg pain from walking.
- Trial name
- NCT01731990
- Testing
- Canakinumab (ACZ885)
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Dyslipidemia
Effect of Compound (Cardiol Forte) on Lipid And Glycemic Parameters in Low Cardiovascular Risk Individuals
This study will evaluate the effects of a combination dietary supplement, Cardiol Forte, on lipid and glycemic parameters in adults at low cardiovascular risk with suboptimal cholesterol levels.
- Trial name
- CLARISKI (NCT07515573)
- Testing
- Cardiol Forte
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- U.G.A. Nutraceuticals
Venous Leg Ulcer
Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
A 12 month, multicenter, open-label registry to observe chronic venous insufficiency resulting in VLU treated with Varithena.
- Trial name
- VIEW-VLU (NCT03257254)
- Testing
- Varithena
- Where
- 14 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- Boston Scientific Corporation
Atherosclerosis, Inflammatory Activity in Coronary Arteries
Exploratory Study of Coronary Flow Reserve Measurements, a Non-Invasive Method for Coronary Function Measurements
The aim of this study is to investigate whether the non-invasive ultrasound method for assessment of coronary blood flow, transthoracic Doppler echocardiography-coronary flow reserve (TTDE-CFR), can be used to measure drug…
- Trial name
- NCT00783042
- Testing
- Rosuvastatin
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Atherosclerosis, Myocardial Ischemia
Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)
The study is designed to assess safety and effects of vorapaxar, when added to standard of care (aspirin and clopidigrel), in Japanese subjects with acute coronary syndrome.
- Conditions
- Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT00684203
- Testing
- Vorapaxar, Aspirin, Clopidogrel
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
COPD, Sepsis
Effect of Nebulized Bronchodilators on Heart Rate
The purpose of the study is to determine adverse events rates of nebulized albuterol versus levalbuterol among adult critically ill patients and determine if a differential exists in adverse events between the two drugs.
- Conditions
- COPD, Sepsis, Shock
- Trial name
- NCT01151579
- Testing
- Levalbuterol, Albuterol
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Fahim Khorfan, MD
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Acute Coronary Syndrome
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile.
- Trial name
- dal-GenE-2 (NCT05918861)
- Testing
- Dalcetrapib
- Where
- 231 sites in United States, Canada and 1 more
- Volunteers
- 2,000 people
- Sponsor
- DalCor Pharmaceuticals
Hypertension
A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients
The purpose of this study is to evaluate the effects of various doses of nebivolol in patients with mild to moderate hypertension.
- Trial name
- NCT00200460
- Testing
- Nebivolol
- Where
- United States
- Volunteers
- 825 people
- Sponsor
- Mylan Bertek Pharmaceuticals
Atherosclerosis
A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis
The purpose of this study is to determine the efficacy of treatment with olmesartan medoxomil, an Angiotensin Receptor Blocker, compared to placebo on the blood levels of surrogate markers of vascular inflammation for…
- Trial name
- NCT00382213
- Testing
- Olmesartan medoxomil
- Volunteers
- 210 people
- Sponsor
- Daiichi Sankyo
Blood Pressure, High, Blood Sugar; High
Observe the Effect of Wheatgrass and Tulsi Formulation or Individuals Taken With Other Allopathic Drugs
Antioxidant qualities have been attributed to wheatgrass and tulsi formulation. Free radicals are unstable molecules created by the body during metabolism and exposure to environmental pollutants.
- Conditions
- Blood Pressure, High, Blood Sugar; High, Weight, Birth, Smoking
- Trial name
- NCT05851040
- Testing
- Observation study
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Swalife Biotech
Coronary Artery Disease (CAD)
Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients
The aim of this study is to demonstrate that the combination therapy of aspirin and clopidogrel napadisilate is not inferior to that of aspirin and clopidogrel bisulfate with respect to its effectiveness in inhibiting platelet…
- Trial name
- NCT01830491
- Testing
- Clopidogrel, aspirin 100mg
- Volunteers
- 162 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes Mellitus
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and…
- Trial name
- NCT02465515
- Testing
- Albiglutide 30 mg, Albiglutide 50 mg
- Where
- 607 sites in United States, Argentina and 26 more
- Volunteers
- 9,463 people
- Sponsor
- GlaxoSmithKline
Diabetes Type 2, Hyperglycaemia (Diabetic)
Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM
Diabetes is a significant risk factor for sudden cardiac death, with the QTc interval on electrocardiograms (ECGs) often prolonged in diabetic patients due to factors such as hyperglycaemia and insulin resistance.
- Conditions
- Diabetes Type 2, Hyperglycaemia (Diabetic), QT Interval, Variation in, Torsades de Pointes
- Trial name
- NCT07014735
- Testing
- glucose, moxifloxacin
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Richmond Pharmacology Limited
Fabry Disease
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
This is a 12-month, parallel treatment, Phase 3, double-blind, randomized, placebo-controlled study to evaluate the effect of venglustat on neuropathic and abdominal pain symptoms of Fabry disease in participants ≥16 years of age…
- Trial name
- PERIDOT (NCT05206773)
- Testing
- Venglustat (GZ402671)
- Where
- 50 sites in United States, Argentina and 19 more
- Volunteers
- 122 people
- Sponsor
- Sanofi
Cardiovascular Risk Factors
Study on Effects of a Dairy Product Based on Polyphenols and Enriched With Vitamins B6, B9 and B12 on Some Cardiovascular Factor of Risk
We put forward that polyphenols and vitamins have a cardiovascular prevention effect for subject with cardiovascular risk.
- Trial name
- NCT00706888
- Testing
- Vitamins B6, B9 and B12 and polyphenols
- Where
- France
- Volunteers
- 64 people
- Sponsor
- Elvir SAS
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
- Conditions
- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
- Trial name
- ASCEND-ATTR (NCT07695701)
- Testing
- Acoramidis (AG10) oral tablet
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Atrial Fibrillation
A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
The purpose of this study is to look at how many patients with AF had strokes, major bleeding and death in both people who had and had not taken any oral anticoagulant.
- Trial name
- SIFNOS (NCT05838664)
- Testing
- No OAC, VKA, apixaban
- Where
- France
- Volunteers
- 2,140,403 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, Atherosclerosis
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
This study will evaluate the effect of ACZ885 on vascular function in patients with documented atherosclerotic disease and T2DM or IGT.
- Conditions
- Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
- Trial name
- NCT00995930
- Testing
- ACZ885
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals